525 results on '"Factor V Leiden mutation"'
Search Results
502. Factor V Leiden Mutation in Women with Idiopathic Pulmonary Embolism
- Author
-
Jørn Olsen and Birthe Søgaard Andersen
- Subjects
medicine.medical_specialty ,business.industry ,Internal medicine ,Cardiology ,Medicine ,Hematology ,Factor V Leiden mutation ,business ,medicine.disease ,Pulmonary embolism - Published
- 1997
503. Association between factor V Leiden mutation and poor pregnancy outcomes among Palestinian women
- Author
-
Hussein, Ayman S., Darwish, Hisham, and Shelbayeh, Khaled
- Subjects
- *
PREGNANCY complications , *BLOOD coagulation factors , *BLOOD diseases , *GENETIC mutation , *RECURRENT miscarriage , *GENETIC polymorphisms , *GENETICS - Abstract
Abstract: Pregnancy is a hypercoagulable state with increased tendency for thrombus formation, a condition that is increased when combined with acquired or inherited risk factors that lead to thrombophilia. Among the inherited risk factors is Factor V Leiden mutation, an autosomal dominant trait with reduced penetrance. The mutation seems to be associated with different poor pregnancy outcomes including recurrent miscarriages. In the present study, we performed a case-control study to investigate the association between the Leiden mutation and poor pregnancy outcome among the Palestinian population in the West bank region of Palestine. The study included 145 subjects with recurrent miscarriages and 205 matched control subjects with successful pregnancies who experienced normal delivery and no apparent complications. Leiden mutation was detected in 41 of the145 study subjects (28.2%), and in 24 of the 205 control subjects (11.7%). Subjects homozygous with the mutant allele were identified only among the test and not the control group. Data analysis indicates a significant association between the mutant allele and recurrent miscarriages (p-value<0.05). Furthermore, this association is significant between the mutant haplotype with miscarriages compared to control group showing time effect where there is no association for miscarriages before week 10. Results here also show strong association of factor V leiden polymorphism among primary aborters compared to secondary aborters or control groups. The odds ratio for the primary aborters was 75 and p<0.0001. In conclusion, these results provide evidence for a significant correlation between recurrent miscarriages and Factor V mutation in our population. [Copyright &y& Elsevier]
- Published
- 2010
- Full Text
- View/download PDF
504. P3. Development of an ARMS procedure for the factor V Leiden mutation
- Author
-
G. Dolan, G A Scobie, N A Kalsheker, and S. T. Ho
- Subjects
Genetics ,Hematology ,General Medicine ,Factor V Leiden mutation ,Biology - Published
- 1996
505. PREVALENCE OF THE FACTOR V LEIDEN MUTATION IN CHILDREN AND NEONATES WITH THROMBOEMBOLIC DISEASE. ▴ 917
- Author
-
Johannes Walter, Catherine S. Manno, J. Nathan Hagstrom, Katherine A. High, and Rachel Bluebond-Langner
- Subjects
congenital, hereditary, and neonatal diseases and abnormalities ,Pediatrics ,medicine.medical_specialty ,business.industry ,hemic and lymphatic diseases ,Pediatrics, Perinatology and Child Health ,Medicine ,Thromboembolic disease ,cardiovascular diseases ,Factor V Leiden mutation ,business ,female genital diseases and pregnancy complications - Abstract
PREVALENCE OF THE FACTOR V LEIDEN MUTATION IN CHILDREN AND NEONATES WITH THROMBOEMBOLIC DISEASE. ▴ 917
- Published
- 1996
506. Detection of the factor V Leiden mutation in a nonselected black population [letter]
- Author
-
Paul S. Pottinger, F Sigurdsson, and Nancy Berliner
- Subjects
Genetics ,education.field_of_study ,business.industry ,Population ,Immunology ,Medicine ,Factor V Leiden mutation ,Cell Biology ,Hematology ,business ,education ,Biochemistry - Published
- 1996
507. Obstetrical complications in women with the factor V Leiden mutation
- Author
-
Donna Dizon-Townson
- Subjects
medicine.medical_specialty ,Obstetrics ,business.industry ,medicine ,Obstetrics and Gynecology ,Obstetrical complications ,Factor V Leiden mutation ,business - Published
- 1996
508. Fatal Cerebral Venous Sinus Thrombosis Associated with the Factor V Leiden Mutation and the Use of Oral Contraceptives
- Author
-
Françoise Bridey, Laissy Jp, Lefebvre M, Wolff M, Morin, and de Prost D
- Subjects
medicine.medical_specialty ,Text mining ,business.industry ,Medicine ,Hematology ,Factor V Leiden mutation ,Cerebral venous sinus thrombosis ,business ,medicine.disease ,Surgery - Published
- 1995
509. Time to conception and time to live birth in women with unexplained recurrent miscarriage.
- Author
-
Kaandorp SP, van Mens TE, Middeldorp S, Hutten BA, Hof MH, van der Post JA, van der Veen F, and Goddijn M
- Subjects
- Abortion, Habitual etiology, Adult, Cohort Studies, Female, Fertilization in Vitro, Humans, Pregnancy, Prognosis, Prospective Studies, Time Factors, Treatment Outcome, Young Adult, Abortion, Habitual therapy, Fertilization physiology, Live Birth
- Abstract
Study Question: What is the time to conception in a cohort of women with unexplained recurrent miscarriage (RM)., Summary Answer: Median time to conception in women diagnosed with unexplained RM was 21 weeks (interquartile range (IQR) 8-55 weeks), with a cumulative incidence of conception of 74% after 12 months of trying to conceive., What Is Known Already: There is no effective treatment in couples with unexplained RM. Adequate counselling about their prognosis, for example time to conception and time to a live birth, is therefore very important. So far, there are no studies that give insight on these issues., Study Design, Size, Duration: A nested prospective cohort study was performed from February 2004 through July 2009 within a multicentre randomized placebo-controlled trial (ALIFE trial) on anticoagulant treatment in 364 women with unexplained RM., Participants/materials, Setting, Methods: A total of 251 women who were not pregnant at the time of diagnosis of unexplained RM were included in this study. Of these, 13% became pregnant with ART, and all other women conceived naturally. The primary outcome was time to conception in weeks, calculated from the moment of diagnosis until conception measured by a urinary HCG. Secondary outcome was time to a live birth in the subsequent pregnancy. The relative prognostic significance of female age, the number of preceding miscarriages, interventions within the trial and the presence or absence of a preceding late miscarriage, a previous live birth and factor V Leiden mutation, was evaluated by Cox regression for time to conception and by competing risk modelling for time to live birth, respectively., Main Results and the Role of Chance: The cumulative incidence of conception was 56% after 6 months, 74% after 12 months and 86% after 24 months of which 65% resulted in a live birth. The median time to conception was 21 weeks (IQR 8-55 weeks). Of potential prognostic factors, the presence of the factor V Leiden mutation resulted in a significantly shorter median time to conception of 11 weeks for carriers versus 23 weeks for non-carriers (hazard ratio (HR) 1.94, 95% confidence interval (CI) 1.03-3.65). The cumulative incidence of a live birth of the subsequent pregnancy was 0% after 6 months, 23% after 12 months and 50% after 24 months. The median time to a live birth of the subsequent pregnancy was 102 weeks (IQR 82-115 weeks). The number of previous miscarriages was the only prognostic factor (HR 0.83, 95% CI 0.74-0.94) significantly associated with time to a live birth of the subsequent pregnancy., Limitations, Reasons for Caution: In our study only the subsequent pregnancy after diagnosing unexplained RM was included. A future collection of cumulative follow-up data of all the women included in this cohort may provide outcomes of all pregnancies following the diagnosis of unexplained RM., Wider Implications of the Findings: Time to conception in women diagnosed with unexplained RM appears to be comparable with time to conception in healthy fertile women, as reported in the literature. The interesting finding that women with Factor V Leiden mutation have a significant shorter time to conception may suggest a favourable embryo implantation process. Future research is needed to confirm these findings and unravel the biology of early implantation., Study Funding/competing Interest(s): The RCT used for this nested cohort study was funded by a grant (945-27-003) from the Netherlands Organization for Health Research and Development and a grant from GlaxoSmithKline. Study drugs (aspirin and placebo) were packaged and donated by Meda Pharma. This analysis was supported by a VIDI innovative research grant from the Netherlands Organisation for Scientific Research (NWO) 016.126.364. There are no potential conflicts of interest to declare., Trial Registration Number: This cohort study was nested in the randomized controlled trial; ALIFE study (Current Controlled Trials number, ISRCTN 58496168).
- Published
- 2014
- Full Text
- View/download PDF
510. Should women suffering from migraine with aura be screened for biological thrombophilia?: results from a cross-sectional French study.
- Author
-
Maitrot-Mantelet L, Horellou MH, Massiou H, Conard J, Gompel A, and Plu-Bureau G
- Subjects
- Adolescent, Adult, Cross-Sectional Studies, Female, France epidemiology, Humans, Middle Aged, Migraine with Aura blood, Risk Factors, Stroke etiology, Surveys and Questionnaires, Thrombophilia diagnosis, Young Adult, Migraine with Aura epidemiology, Stroke epidemiology, Thrombophilia epidemiology
- Abstract
Introduction: Migraine, particularly migraine with aura (MA), is associated with a higher risk for ischemic stroke (IS). A procoagulant state may predispose to IS. Whether inherited biological thrombophilia are associated with migraine risk remains controversial., Objective: To assess the risk of migraine without or with aura related to inherited biological thrombophilia adjusted for the main potential confounders., Material and Methods: A cross-sectional study was conducted in 1456 French women aged 18 to 56years, referred for biological coagulation check-up because of personal or familial venous thrombosis history. Between April 2007 and December 2008, all women answered a self-administered questionnaire to determine whether they had headache., Results: There were 294 (20%) migrainous sufferers (including 71 [5%] with MA), 975 (67%) non migrainous women and 187 (13%) non migrainous headache women. Inherited thrombophilia were detected in 576 (40%) women, including 389 (40%) non migrainous women, 90 (40%) migraine without aura (MWA), 33 (46%) MA women and 64 (34%) non migrainous headache women. Factor V Leiden (FVL) i.e. F5rs6025 or Factor II G20210A (FIIL) i.e. F2rs1799963 mutation was detected in 296 (30%) non migrainous women and in 100 (34%) migrainous women of which 27 had MA. There was a significant association between MA and FVL or FIIL mutations (adjusted OR=1.76 [95% CI 1.02-3.06] p=0.04) whereas this association in MWA and in non migrainous headache women was not significant. There was no significant association between migraine and other biological thrombophilia., Conclusion: FVL or FIIL mutations were more likely among patients suffering from MA. Whether biological thrombophilia screening should be systematically performed in women suffering from MA remains to be determined., (Copyright © 2014. Published by Elsevier Ltd.)
- Published
- 2014
- Full Text
- View/download PDF
511. Recurrent pregnancy loss in a subject with heterozygote factor V Leiden mutation; a case report.
- Author
-
Ebrahimzadeh-Vesal R, Azam R, Ghazarian A, Hajesmaeili M, Ranji N, Ezzati MR, Sadri M, Mohammadi MA, and Khavandi S
- Abstract
Recurrent pregnancy loss is usually defined as the loss of two or more consecutive pregnancies before 20 weeks of gestation, which occurs in approximately 5% of reproductive-aged women. It has been suggested that women with thrombophilia have an increased risk of pregnancy loss and other adverse pregnancy outcomes. Thrombophilia is an important predisposition to blood clot formation and is considered as a significant risk factor for recurrent pregnancy loss. The inherited predisposition to thrombophilia is most often associated with factor V Leiden mutation, prothrombin G20210A mutation, and methylenetetrahydrofolate reductase C677T and A1298C gene variants. The net effect is an increased cleavage of prothrombin to thrombin and excessive blood coagulation.
- Published
- 2014
512. Maternal factor V Leiden and prothrombin mutations do not seem to contribute to the occurrence of two or more than two consecutive miscarriages in Caucasian patients.
- Author
-
Baumann K, Beuter-Winkler P, Hackethal A, Strowitzki T, Toth B, and Bohlmann MK
- Subjects
- Abortion, Habitual enzymology, Adult, Cohort Studies, Female, Humans, Methylenetetrahydrofolate Reductase (NADPH2) genetics, Polymorphism, Genetic genetics, Retrospective Studies, Abortion, Habitual genetics, Factor V genetics, Mutation, Prothrombin genetics, White People genetics
- Abstract
Background: We analysed the prevalence of the most common hereditary thrombophilia (hTP) - factor V Leiden (FVL) mutation, prothrombin 20210 G>A substitution (PT) - and the 677 C>T replacement in the 5,10-methylenetetrahydrofolate reductase (MTHFR) gene in Caucasian patients with a history of two and more consecutive recurrent miscarriages (RMs) as compared to healthy controls with an identical ethnic background and at least one live birth., Methods: A multicenter analysis of three hTP was performed in 641 RM patients identically screened at specialized university centres., Results: The study groups consisted of 240 patients with 2 (1) and 401 patients with >2 miscarriages (2) and were compared with 157 controls. There was no significant difference in the prevalence of the hTP between RM patients and controls nor within the two study groups. Subgroup analysis showed that the homozygous MTHFR polymorphism was significantly more prevalent in the study group 2 as compared to study group 1 (13.9 versus 7.9%, P = 0.02)., Conclusion: In Caucasians, maternal FVL or PT mutations do not seem to contribute to the pathophysiology of RM, irrespective of the number of miscarriages. However, the role of the homozygous MTHFR polymorphism merits further investigation., (© 2013 John Wiley & Sons Ltd.)
- Published
- 2013
- Full Text
- View/download PDF
513. Meta-analysis of Factor V Leiden G1691A polymorphism and osteonecrosis of femoral head susceptibility.
- Author
-
Shang X, Luo Z, Li X, Hu F, Zhao Q, and Zhang W
- Abstract
Testing for genetic risk associations between Factor V Leiden (FVL) and the osteonecrosis of femoral head (ONFH) is common, however, inconsistent results have been previously obtained. To summarize results on the association of FVL mutation polymorphism with ONFH in various populations and to calculate the overall genetic risk factors, we performed a search of electronic databases including PubMed, Elsevier Science Direct, Chinese National Knowledge Infrastructure and the Chinese Biomedical Database to identify published studies correlating the FVL mutation with ONFH. Statistical analysis was performed using Review Manager (RevMan) version 5.0 and Stata statistical software (version 10). We identified 57 titles and included 7 studies comprising 481 cases and 867 controls in this meta-analysis. The groups were pooled, and a significant association between FVL mutation and increased ONFH was found (OR=4.55, 95% CI, 2.75-7.52, P<0.00001). This meta-analysis demonstrated that FVL plays an important role in non-Asian populations. Large sample studies including different ethnic groups and age- and gender-matched groups, as well as multiple gene polymorphism detection should be considered to clarify the association of FVL mutation polymorphism and ONFH susceptibility in the future.
- Published
- 2013
- Full Text
- View/download PDF
514. Factor V Leiden mutation: An added risk in single ventricle palliation.
- Author
-
Saileela R, Shanthi C, Agarwal R, Subramanyan R, and Cherian K
- Abstract
We present the case report of a child with Factor V Leiden mutation who underwent Fontan procedure. Thromboembolism is a widely recognized complication of the Fontan procedure and its modifications. Factor V Leiden mutation, being a hypercoagulable state, posed a higher risk for thromboembolism in this child. Appropriate measures taken before and after surgery prevented postoperative coagulopathy.
- Published
- 2012
- Full Text
- View/download PDF
515. Evaluation the frequency of factor V Leiden mutation in pregnant women with preeclampsia syndrome in an Iranian population.
- Author
-
Karimi S, Yavarian M, Azinfar A, Rajaei M, and Azizi Kootenaee M
- Abstract
Background: Role of genetic factors in etiology of preeclampsia is not confirmed yet., Objective: Gene defect frequency varies in different geographic areas as well as ethnic groups. In this study, the role of factor V Leiden mutation in the pathogenesis of preeclampsia syndrome among the pregnant population of northern shore of Persian Gulf in Iran, were considered., Materials and Methods: Between Jan. 2008 and Dec. 2009, in a nested case control study, pregnant women with preeclampsia (N=198) as cases and healthy (N=201) as controls were enrolled in the study. DNA were extracted from 10 CC peripheral blood and analyzed for presence of factor V Leiden mutation in these subjects. The maternal and neonatal outcomes of pregnancy according to the distribution of factor V Leiden were also compared among cases., Results: In total, 17(8.6%) of cases and 2(1%) of controls showed the factor V Leiden mutation. The incidence of factor V Leiden was typically higher in preeclamptic women than control group (OR: 9.34 %95 CI: 2.12-41.01). There was no difference in incidence rate of preterm delivery< 37 weeks (OR: 1.23 %95 CI: 0.38-4.02), very early preterm delivery<32 weeks (OR: 1.00 %95 CI: 0.12-8.46), intra uterine fetal growth restriction (IUGR) (OR: 1.32 %95 CI: 0.15-11.30 ),and the rate of cesarean section (OR: 0.88 %95 CI: 0.29-2.62 ) among cases based on the prevalence of factor V Leiden mutation., Conclusion: The pregnant women with factor V Leiden mutation are prone for preeclampsia syndrome during pregnancy, but this risk factor was not correlated to pregnancy complications in the studied women.
- Published
- 2012
516. Epidemiological aspects of Budd-Chiari in Egyptian patients: a single-center study.
- Author
-
Sakr M, Barakat E, Abdelhakam S, Dabbous H, Yousuf S, Shaker M, and Eldorry A
- Subjects
- Adult, Budd-Chiari Syndrome etiology, Budd-Chiari Syndrome pathology, Egypt epidemiology, Factor V genetics, Female, Humans, Male, Methylenetetrahydrofolate Reductase (NADPH2) genetics, Mutation, Pregnancy, Pregnancy Complications genetics, Risk Factors, Young Adult, Budd-Chiari Syndrome epidemiology, Budd-Chiari Syndrome genetics
- Abstract
Aim: To describe the socio-demographic features, etiology, and risk factors for Budd-Chiari syndrome (BCS) in Egyptian patients., Methods: Ninety-four Egyptian patients with confirmed primary Budd-Chiari syndrome were presented to the Budd-Chiari Study Group (BCSG) and admitted to the Tropical Medicine Department of Ain Shams University Hospital (Cairo, Egypt). Complete clinical evaluation and laboratory investigations, including a thrombophilia workup and full radiological assessment, were performed to determine underlying disease etiologies., Results: BCS was chronic in 79.8% of patients, acute or subacute in 19.1%, and fulminant in 1.1%. Factor V Leiden mutation (FVLM) was the most common etiological cause of disease (53.1%), followed by mutation of the gene encoding methylene tetrahydrofolate reductase (MTHFR) (51.6%). Current or recent hormonal treatment was documented in 15.5% of females, and BCS associated with pregnancy was present in 17.2% of females. Etiology could not be determined in 8.5% of patients. Males had significantly higher rates of MTHFR gene mutation and Behçet's disease, and females had significantly higher rates of secondary antiphospholipid antibody syndrome. A highly significant positive relationship was evident between the presence of Behçet's disease and inferior vena caval occlusion, either alone or combined with occlusion of the hepatic veins (P < 0.0001)., Conclusion: FVLM is the most common disease etiology and MTHFR the second most common in Egyptian BCS patients. BCS etiology tends to vary with geographic region.
- Published
- 2011
- Full Text
- View/download PDF
517. Successful management of hemopericardium and cardiac tamponade secondary to occult malignancy and anticoagulation.
- Author
-
Hsi DH, Krishnamurthy M, Ryan GF, Luo P, and Woodlock TJ
- Abstract
In patients presenting with pericarditis or pericardial effusion without known malignancy, the likelihood of finding previously undiagnosed cancer in different publications typically ranges from 4% to 7%. Cardiac tamponade due to malignant pericardial effusion is thus a rare clinical entity and often acutely life threatening. The present report describes an unusual case of large pericardial bleeding causing tamponade in the setting of fondaparinux anticoagulation, heterozygous factor V Leiden mutation and eventual discovery of meta-static adenocarcinoma.
- Published
- 2010
518. Anticoagulant factor V: Factors affecting the integration of novel scientific discoveries into the broader framework
- Author
-
Michelle L. LaBonte
- Subjects
History ,Science ,History and Philosophy of Science ,Coagulation cascade ,Factor V Leiden ,medicine ,Humans ,Thrombophilia ,Blood Coagulation ,Medicine(all) ,biology ,Factor V ,Anticoagulant ,Anticoagulants ,General Medicine ,History, 20th Century ,medicine.disease ,Epistemology ,Patient population ,Immunology ,Mutation ,biology.protein ,Factor V Leiden mutation ,Psychology - Abstract
Since its initial discovery in the 1940s, factor V has long been viewed as an important procoagulant protein in the coagulation cascade. However, in the later part of the 20th century, two different scientists proposed novel anticoagulant roles for factor V. Philip Majerus proposed the first anticoagulant function for factor V in 1983, yet ultimately it was not widely accepted by the broader scientific community. In contrast, Björn Dahlbäck proposed a different anticoagulant role for factor V in 1994. While this role was initially contested, it was ultimately accepted and integrated into the scientific framework. In this paper, I present a detailed historical account of these two anticoagulant discoveries and propose three key reasons why Dahlbäck's anticoagulant role for factor V was accepted whereas Majerus' proposed role was largely overlooked. Perhaps most importantly, Dahlbäck's proposed anticoagulant role was of great clinical interest because the discovery involved the study of an important subset of patients with thrombophilia. Soon after Dahlbäck's 1994 work, this patient population was shown to possess the factor V Leiden mutation. Also key in the ultimate acceptance of the second proposed anticoagulant role was the persistence of the scientist who made the discovery and the interest in and ability of others to replicate and reinforce this work. This analysis of two different yet similar discoveries sheds light on factors that play an important role in how new discoveries are incorporated into the existing scientific framework.
- Full Text
- View/download PDF
519. Thrombophilia Due to Factor V and Factor II Mutations and Formation of a Dural Arteriovenous Fistula: Case Report and Review of a Rare Entity.
- Author
-
Safavi-Abbasi S, Di Rocco F, Nakaji P, Feigl GC, Gharabaghi A, Samii M, Valavanis A, and Samii A
- Abstract
Genetic mutations underlying thrombophilia are often recognized in patients with thromboembolic episodes. However, the clinical and therapeutic implications of such findings often remain unclear. We report the first case of a dural arteriovenous fistula (DAVF) in a patient with a combined factor II and factor V Leiden mutation. A 40-year-old man presented with a large left temporal and intraventricular hemorrhage. An initial angiogram showed thrombosis of the left sigmoid sinus but no evidence of a vascular malformation. One year after the hemorrhage, an angiographic study showed the appearance of a right DAVF. During the follow-up period, the patient was found to harbor heterozygosity for a mutation of factor V and a mutation of factor II. Recognition of the patient's thrombophilia led to prolonged oral anticoagulation therapy to reduce the risk of a recurrent thrombotic episode. Despite the increased risk of bleeding, the therapy was considered justified. DAVFs may occur after sinus thrombosis in patients with combined factor II and factor V mutations. This observation indicates the association of multiple hematological disorders with DAVFs in individual patients. Moreover, it raises the clinical conundrum of how to manage patients with thrombophilia, intracranial hemorrhage, and DAVFs.
- Published
- 2008
- Full Text
- View/download PDF
520. Paget-Schroetter syndrome after a dental procedure in a patient with factor V Leiden (R506Q) heterozygosity
- Author
-
Prabin Sharma
- Subjects
Heterozygote ,medicine.medical_specialty ,030204 cardiovascular system & hematology ,Effort thrombosis ,Loss of heterozygosity ,03 medical and health sciences ,0302 clinical medicine ,Upper Extremity Deep Vein Thrombosis ,medicine ,Factor V Leiden ,Coagulopathy ,Humans ,Dental Procedure ,business.industry ,Factor V ,Paget-schroetter syndrome ,Hematology ,General Medicine ,Middle Aged ,medicine.disease ,Surgery ,Female ,Factor V Leiden mutation ,business ,Left upper extremity ,030217 neurology & neurosurgery - Abstract
Paget-Schroetter syndrome or effort thrombosis is characterized by spontaneous thrombosis of the upper extremity venous system, commonly seen in a young healthy patient after repetitive use of the upper extremities. It is rarely associated with coagulopathy and thus, hypercoagulable work-up is not usually a part of the investigation. We present a first case of a young woman, who was diagnosed with left upper extremity effort thrombosis following a dental procedure. Interestingly, she was also noted to be heterozygous for factor V Leiden mutation.
521. [Untitled]
- Subjects
Iliac vein thrombosis ,Iliac artery ,medicine.medical_specialty ,business.industry ,Vein compression ,General Medicine ,musculoskeletal system ,Surgery ,cardiovascular system ,Left common iliac vein ,medicine ,Factor V Leiden mutation ,Mr venography ,Endovascular treatment ,Young female ,business - Abstract
Iliac vein compression syndrome is a condition involving external compression of the left common iliac vein by the right iliac artery, which was first described in the 1850s. It predominates in females typically between the third and fourth decade of life and has been associated with thrombophilias. Importantly, the syndrome is amenable to endovascular treatment. Here, we describe a case of a young athletic female with an incidental finding of a left iliac vein thrombosis while taking oral contraceptives, who was identified as having iliac vein compression syndrome on follow-up MR venography with positive testing for Factor V Leiden mutation.
522. Detection of the factor V Leiden mutation in Iranian patients with venous thrombosis
- Author
-
Ghasem Rastegar Lari, Abbas Hajifathali, Bahram Kazemi, Minoo Ahmadi, Mohammadreza Tabatabaie, Rouzbeh Chegeni, Yadollah Mehrabi, and Ali Akbar Pourfathollah
- Subjects
medicine.medical_specialty ,Venous thrombosis ,business.industry ,Internal medicine ,Medicine ,Factor V Leiden mutation ,business ,medicine.disease ,Gastroenterology ,General Biochemistry, Genetics and Molecular Biology
523. Deep vein thrombosis during varicella in a child with factor V Leiden mutation and familial deficiency of protein S
- Author
-
Giacomo Zanelli, Luca Masotti, Sandro Forconi, Roberto Cappelli, and Stefania Battistini
- Subjects
congenital, hereditary, and neonatal diseases and abnormalities ,Pathology ,medicine.medical_specialty ,biology ,business.industry ,Deep vein ,Vascular biology ,virus diseases ,Hematology ,medicine.disease ,Thrombosis ,female genital diseases and pregnancy complications ,Protein S ,medicine.anatomical_structure ,hemic and lymphatic diseases ,medicine ,biology.protein ,cardiovascular diseases ,Factor V Leiden mutation ,business - Abstract
Deep Vein Thrombosis during Varicella in a Child with Factor V Leiden Mutation and Familial Deficiency of Protein S
524. Multiplex PCR for one-step determination of the G20210A variation and the factor V Leiden mutation by denaturing gradient gel electrophoresis (DGGE)
- Author
-
Sylvie Patri, Mickaël Caillon, Jean-Claude Chomel, Alain Kitzis, and Sandra Salmeron
- Subjects
Venous Thrombosis ,Chemistry ,Vascular biology ,Mutation, Missense ,Factor V ,Hematology ,Molecular biology ,Polymerase Chain Reaction ,Amino Acid Substitution ,hemic and lymphatic diseases ,Multiplex polymerase chain reaction ,Mutagenesis, Site-Directed ,Humans ,Point Mutation ,Thrombophilia ,Electrophoresis, Polyacrylamide Gel ,Genetic Predisposition to Disease ,Prothrombin ,cardiovascular diseases ,Factor V Leiden mutation ,3' Untranslated Regions ,Hypoprothrombinemias ,Temperature gradient gel electrophoresis ,Activated Protein C Resistance - Abstract
Multiplex PCR for One-step Determination of the G20210A Variation and the Factor V Leiden Mutation by Denaturing Gradient Gel Electrophoresis (DGGE)
525. Factor V Leiden mutation in patients with breast cancer and a central venous catheter: Relationship with deep vein thrombosis
- Author
-
Giulia Peruzzotti, Paolo Bucciarelli, A. Goldhirsch, Mario Mandalà, F. de Braud, Pier Giuseppe Pelicci, Giuseppe Curigliano, M.A. Colleoni, Roberto Biffi, and P. M. Mannucci
- Subjects
Cancer Research ,medicine.medical_specialty ,business.industry ,medicine.medical_treatment ,Deep vein ,Cancer ,medicine.disease ,Thrombosis ,Surgery ,medicine.anatomical_structure ,Breast cancer ,Oncology ,Coagulation ,Medicine ,In patient ,cardiovascular diseases ,Factor V Leiden mutation ,business ,Central venous catheter - Abstract
8020 Background: Disorders of coagulation are encountered in up to 90% of cancer patients (pts), although only 15% of them develop a localized acute or chronic deep venous thrombosis (DVT) or a dis...
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.